Redhill Biopharma Stock News

Can these penny stocks make gains this coming week? The post Hot Penny Stocks to Buy Right Now? Check These 3 Out appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Can these penny stocks make gains this coming week? The post Hot Penny Stocks to Buy Right Now?

Gainers ToughBuilt Industries, Inc. (NASDAQ: TBLT) rose 58% to $2.75 in pre-market trading after jumping 26% on Thursday. ToughBuilt Industries reported closing of $6 million public offering. Zendes

RedHill Biopharma Ltd. (NASDAQ:RDHL ) Q1 2022 Results Conference Call June 23, 2022 8:30 AM ET Company Participants Debbie Bechor - Business Development & Communications Manager Dror Ben-Asher - Chief

RedHill Biopharma Ltd (NASDAQ: RDHL) plans announced a cost reduction plan expected to generate operational cost savings of approximately $50 million over the next 18 months. Most of these savings r

TEL AVIV, Israel and RALEIGH, N.C. , June 17, 2022 /PRNewswire/ -- RedHill Biopharma Ltd.

Redhill Biopharma Ltd. (RDHL) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreeme

RedHill Biopharma Ltd's (NASDAQ: RDHL) opaganib (ABC294640), an oral drug candidate for hospitalized COVID-19 patients, demonstrated potent in vitro efficacy against the omicron variant while maint

    RedHill Biopharma Ltd Announces Potent Omicron Inhibition with RedHill's Opaganib   Oral opaganib's reported potent in vitro activity against Omicron adds to previously observed inhibition of Delta and other SARS-CoV-2 variants of concern that cause COVID-19; Testing conducted by The University of Hong Kong School of Public Health, a world renowned WHO collaborating center     -- Based on the new and previously announced data, opaganib'...

RedHill Biopharma Ltd. (RDHL) CEO Dror Ben-Asher on Q4 2021 Results - Earnings Call Transcript

  RedHill Biopharma Reports Operational Highlights and Fourth Quarter & Full Year 2021 Financial Results   Record annual and quarterly revenues of $85.8 and $22.1 million respectively – 2021 revenues up 33.2% vs. 2020, gross profit up 32.4% vs. 2020[1] -- Cash balance[2] of $54.2 million as of December 31, 2021 -- Overall contribution of commercial operations to the company was positive for the first time in Q4, and commercial contribution is expe...

Companies Reporting Before The Bell • TransGlobe Energy (NASDAQ: TGA ) is estimated to report earnings for its fourth quarter. • Ikena Oncology (NASDAQ: IKNA ) is projected to report earnings for its fourth quarter. • RF Industries (NASDAQ: RFIL ) is likely to report quarterly earnings at $0.04 per share on revenue of $15.84 million. • Destination XL Group (NASDAQ: DXLG ) is estimated to report quarterly earnings at $0.13 per share on revenue of $131.88 million. • Liquidia (NASDAQ: LQDA ) is projected to report quarterly loss at $0.11 per share on revenue of $3.05 million. • IMV (NASDAQ: IMV ) is projected to report quarterly loss at $0.13 per share on revenue of $50.00 thousand. • Redhill Biopharma (NASDAQ: RDHL ) is likely to report quarterly loss at $0.33 per share on revenue of $24.08 million. • Designer Brands (NYSE: DBI ) is likely to report quarterly earnings at $0.16 per share on revenue of $839.61 million. • Kirkland''s (NASDAQ: KIRK ) is expected to report quarterly earnings at $0.

RedHill Biopharma Ltd (NASDAQ: RDHL ) has entered into an exclusive license agreement with Kukbo Co Ltd for oral opaganib to treat COVID-19 in South Korea. Under the terms of the license agreement, which follows the previously announced strategic investment by Kukbo, RedHill will receive an upfront payment of $1.5 million. Redhill is eligible for up to $5.6 … Full story available on Benzinga.com

RedHill Biopharma (RDHL) signed an exclusive license agreement with Kukbo for oral opaganib to treat COVID-19, in South Korea

RedHill Biopharma Ltd (NASDAQ: RDHL) has entered into an exclusive license agreement with Kukbo Co Ltd for oral opaganib to treat COVID-19 in South Korea.  Under the terms of the license agreeme